Researchers compared the outcomes of liver-confined unresectable intrahepatic cholangiocarcinoma (ICCA) patients receiving systemic chemotherapy (gemcitabine and cisplatin) with those given hepatic arterial infusion pump (HAIP) chemotherapy. The study, involving 268 patients, revealed that HAIP chemotherapy significantly outperformed systemic treatment. Median survival for HAIP was 27.7 months compared to 11.8 months with gem-cis. Notably, HAIP resulted in a 3-year survival rate of 34.3%, while gem-cis showed only 3.5%. HAIP chemotherapy presents a substantial advantage for ICCA patients.
Journal Article by Franssen S, Holster JJ (…) Groot Koerkamp B et 16 al. in Ann Surg Oncol
© 2023. The Author(s).